Eyenovia, Inc. - Common Stock (OQ:EYEN)

Apr 08, 2024 07:00 am ET
Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities
Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company, today announced its plans for accelerating development of its potential multi-billion dollar product for pediatric progressive myopia (MicroPine) and initiated a process to...
Apr 03, 2024 07:00 am ET
Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings
Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company, today announced that the company will be conducting demonstrations of its portfolio of commercial products at two upcoming ophthalmology medical meetings. “Our presence at...
Mar 18, 2024 04:05 pm ET
Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company, today announced its financial and operating results for the fourth quarter and full-year ended December 31, 2023. Fourth Quarter 2023 and Recent Business Developments Announced...
Mar 13, 2024 07:00 am ET
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Eyenovia, Inc. (Nasdaq: EYEN) announced the signing of a co-promotion agreement to commercialize prescription ophthalmic products to eyecare professionals across the U.S. Under the agreement,...
Mar 11, 2024 07:00 am ET
Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th
Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic pharmaceutical technology company, today announced that the Company will release financial results for the fourth quarter ended December 31, 2023 on Monday, March 18th, 2024, after the...
Mar 05, 2024 08:00 am ET
Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery
Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company, today congratulates Formosa Pharmaceuticals (TWO:6838) on the FDA approval of clobetasol propionate ophthalmic suspension 0.05% for the treatment of post-operative inflammation...
Feb 13, 2024 07:00 am ET
Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility
Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company, today announced that the company’s facility in Redwood City, California successfully completed FDA inspection for approval as a commercial manufacturing facility. The Redwood...
Jan 16, 2024 07:00 am ET
Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine in the U.S. and Canada
Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage, ophthalmic company, today announced that it has re-acquired the rights to MicroPine in the U.S. and Canada. MicroPine, an investigational eight microliter ophthalmic spray of atropine delivered...
Nov 13, 2023 04:05 pm ET
Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update
Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage, topical ophthalmic company leveraging its Optejet® dispensing technology for both internally developed and acquired programs as well as out-licensing for additional indications, today announced its...
Nov 06, 2023 08:00 am ET
Eyenovia to Report Third Quarter 2023 Results on Monday, November 13
Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ for mydriasis, preparing for regulatory approval of APP13007 for relief of pain and inflammation post ocular surgery, and incorporating its advanced Optejet®...
Nov 02, 2023 07:00 am ET
Eyenovia Announces FDA Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production
Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ for mydriasis, preparing for regulatory approval of APP13007 for relief of pain and inflammation post ocular surgery, and incorporating its advanced Optejet®...
Oct 30, 2023 07:00 am ET
Eyenovia to Sponsor Course on Drug Delivery Innovation at IJCAHPO’s 51st Annual Continuing Education (ACE) Program
Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ for mydriasis, preparing for regulatory approval of APP130007 for relief of pain and inflammation post ocular surgery, and incorporating its advanced Optejet®...
Oct 09, 2023 07:00 am ET
Eyenovia to Present Data on Preservative-Free Microbial Integrity of the Optejet®
Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ for mydriasis, preparing for regulatory approval of APP13007 for relief of pain and inflammation post ocular surgery, and incorporating its advanced Optejet®...
Sep 21, 2023 08:00 am ET
Eyenovia to Participate in Panel Discussion at Cantor Global Healthcare Conference
Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic technology company commercializing Mydcombi™ for mydriasis, preparing for regulatory approval of AP13007 for relief of pain and inflammation post ocular surgery, and incorporating its advanced Optejet®...
Sep 07, 2023 08:00 am ET
Eyenovia to Present at Upcoming H.C. Wainwright 25th Annual Global Investment Conference
Eyenovia, Inc. (Nasdaq: EYEN), a commercial-stage ophthalmic technology company commercializing Mydcombi™ (tropicamide+phenylephrine ophthalmic spray for mydriasis) and developing the Optejet® device for use both in connection with its own...
Aug 24, 2023 06:47 pm ET
Eyenovia Announces $12 Million Registered Direct Offering
Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic technology company commercializing Mydcombi™ (tropicamide+phenylephrine ophthalmic spray for mydriasis) and developing the Optejet® device for use both in connection with its own...
Aug 16, 2023 06:00 am ET
Eyenovia Acquires U.S. Commercial Rights to APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) from Formosa Pharmaceuticals
Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5% for mydriasis and developing the Optejet® device for use both in connection with its...
Aug 10, 2023 04:05 pm ET
Eyenovia Reports Second Quarter 2023 Financial Results and Provides Business Update
Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ (tropicamide+phenylephrine ophthalmic spray) for mydriasis and developing the Optejet® device for use both in connection with its own drug-device therapeutic...
Aug 09, 2023 08:00 am ET
Eyenovia to Present at Upcoming H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic technology company commercializing Mydcombi™ (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5% for mydriasis and developing the Optejet® device for use both in connection with its...
Aug 07, 2023 08:00 am ET
Eyenovia to Report Second Quarter 2023 Results on Thursday, August 10
Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ (tropicamide+phenylephrine ophthalmic spray) for mydriasis and developing the Optejet® device for use both in connection with its own drug-device therapeutic...
Aug 03, 2023 08:00 am ET
Eyenovia Announces First Commercial Sale of Mydcombi™
Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5% for mydriasis and developing the Optejet® device for use both in connection with its...
Jun 26, 2023 08:00 am ET
Eyenovia Announces Addition to Russell 2000® and Russell 3000® Indexes
Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic technology company preparing for the launch of Mydcombi™ (tropicamide+phenylephrine ophthalmic spray for mydriasis) and developing the Optejet® device for use both in connection with its...
Jun 15, 2023 08:54 am ET
Glancy Prongay & Murray LLP Announces Investigation of Eyenovia, Inc. (EYEN)
Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Eyenovia, Inc. (Nasdaq: EYEN) concerning the Company and its directors’ and officers’ possible violations of state laws.
Jun 06, 2023 09:00 am ET
Eyenovia Expands Its US Manufacturing Capabilities
Eyenovia is stepping up the capabilities of its facilities and taking advantage of the thriving innovation culture and expertise in Reno, Nevada, and Redwood City, California
Jun 01, 2023 08:00 am ET
Eyenovia Announces Presentation at the OCTANE Ophthalmology Tech Forum 2023
Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company developing the Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as...
May 11, 2023 04:05 pm ET
Eyenovia Reports First Quarter 2023 Financial Results and Provides Business Update
Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company developing the Optejet delivery system for use both in combination with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as...
May 08, 2023 10:15 am ET
Glancy Prongay & Murray LLP Announces Investigation of Eyenovia, Inc. (EYEN)
Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Eyenovia, Inc. (Nasdaq: EYEN) concerning the Company and its directors’ and officers’ possible violations of state laws.
May 08, 2023 08:00 am ET
Eyenovia Announces FDA Approval of Mydcombi™, the First Ophthalmic Spray for Mydriasis, Which Also Leverages the Company’s Proprietary Optejet® Device Platform
Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company developing the Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as...
May 04, 2023 08:00 am ET
Eyenovia to Report First Quarter 2023 Results on Thursday, May 11
Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs as well as out-licensing for additional indications,...
Apr 24, 2023 08:00 am ET
Eyenovia Announces Poster Presentation at ARVO 2023
Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive...
Mar 30, 2023 04:05 pm ET
Eyenovia Reports Fourth Quarter 2022 Financial Results and Provides Business Update
Eyenovia, Inc. (Nasdaq: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive...
Mar 23, 2023 08:00 am ET
Eyenovia to Report Fourth Quarter and Full-Year 2022 Results on Thursday, March 30
Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs as well as out-licensing for additional indications,...
Feb 28, 2023 04:05 pm ET
Eyenovia Announces Independent Director Stephen Benjamin to Step Down to Assume Role of Head of White House’s Office of Public Engagement
Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive...
Feb 15, 2023 09:51 am ET
Eyenovia Announces Development Collaboration Agreement with Formosa Pharmaceuticals
Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive...
Jan 12, 2023 08:00 am ET
Eyenovia Reveals Positive Evidence That Optejet® Delivery Technology Decreased Inflammation From Preserved Glaucoma Solutions Compared to Drops
Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive...
Dec 20, 2022 08:00 am ET
Eyenovia Announces Participation at the 2023 International Consumer Electronics Show
Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive...
Dec 13, 2022 08:00 am ET
Eyenovia Announces FDA Acceptance of New Drug Application for MydCombi™ for In-Office Pupil Dilation
Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive...
Dec 08, 2022 08:00 am ET
Eyenovia Announces Promotion of Bren Kern to Chief Operating Officer and Corporate Vice President
Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive...
Nov 29, 2022 08:00 am ET
Eyenovia Announces $15 Million Credit Facility with Avenue Venture Debt Fund
Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive...
Nov 23, 2022 04:05 pm ET
Eyenovia to Present at Upcoming BTIG Ophthalmology Day
Eyenovia, Inc. (Nasdaq: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive...
Nov 10, 2022 04:05 pm ET
Eyenovia Reports Third Quarter 2022 Financial Results and Provides Business Update
Eyenovia, Inc. (Nasdaq: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive...
Nov 03, 2022 08:00 am ET
Eyenovia to Report Third Quarter 2022 Results on Thursday, November 10
Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs as well as out-licensing for additional indications,...
Oct 21, 2022 08:00 am ET
Eyenovia to Present at the American Academy of Optometry’s Annual Meeting
Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs as well as out-licensing for additional indications,...
Oct 20, 2022 08:00 am ET
Eyenovia Announces Positive Results from VISION-2 Phase 3 Study of MicroLine as a Potential On-Demand Treatment for Presbyopia
Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive...
Oct 05, 2022 09:31 am ET
Thinking about buying stock in Toughbuilt Industries, Acumen Pharmaceuticals, Ford, FingerMotion, or Eyenovia?
NEW YORK, Oct. 5, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TBLT, ABOS, F, FNGR, and EYEN.
Sep 30, 2022 08:00 am ET
Eyenovia Announces Planned Retirement of Lead Independent Director Ken Lee, Jr.
Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs as well as out-licensing for additional indications,...
Sep 07, 2022 08:00 am ET
Eyenovia to Present at Upcoming Healthcare Conferences
Eyenovia, Inc. (Nasdaq: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced they will present at the R.W. Baird Global...
Sep 06, 2022 09:31 am ET
Thinking about buying stock in Applied DNA Sciences, Hoth Therapeutics, Peabody Energy, Eyenovia, or Nio?
NEW YORK, Sept. 6, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APDN, HOTH, BTU, EYEN, and NIO.
Sep 06, 2022 08:00 am ET
Eyenovia to Participate in Multiple Medical Meetings in September
Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™) therapeutics, today announced that the company will be participating in multiple medical meetings in...
Aug 10, 2022 04:05 pm ET
Eyenovia Reports Second Quarter 2022 Financial Results
Eyenovia, Inc. (Nasdaq: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced its financial and operating results for the...
Aug 04, 2022 08:00 am ET
Eyenovia to Report Second Quarter 2022 Results on Wednesday, August 10
Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, announced that the Company will release financial results for the second quarter ended June 30, 2022...
Jul 27, 2022 08:00 am ET
Eyenovia Announces Appointment of Ophthalmic Industry Veteran Michael Rowe as Chief Executive Officer and Board Member
Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™) therapeutics, today announced the appointment of current Chief Operating Officer Michael Rowe as the...
Jul 18, 2022 08:00 am ET
Eyenovia Provides Manufacturing Update and Announces Appointment of Bren Kern as SVP of Manufacturing and Operations
Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™) therapeutics, today provided an update on its expanded manufacturing capabilities and also announced the...
Jul 07, 2022 08:00 am ET
Eyenovia Announces Appointments of Dr. Ellen Strahlman and Dr. Ram Palanki as New and Independent Members of its Board of Directors
Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™) therapeutics, today announced that it has appointed Dr. Ellen Strahlman and Dr. Ram Palanki as new and...
Jul 06, 2022 08:00 am ET
Eyenovia Strategic Partner Arctic Vision Enrolls First Patient in Phase III Clinical Trial of ARVN003 (MicroLine) for Presbyopia in China
Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™) therapeutics, today announced that its strategic partner, Arctic Vision, a China-based biotech company...
Jun 09, 2022 10:09 am ET
UPDATE: Eyenovia Announces Virtual 2022 Annual Meeting of Stockholders
Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) investigational products, today announced that its Annual Meeting of Stockholders (the "Annual Meeting") will be...
Jun 09, 2022 08:00 am ET
Eyenovia Announces Virtual 2022 Annual Meeting of Stockholders
Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) investigational products, today announced that its Annual Meeting of Stockholders (the "Annual Meeting") will be...
Jun 07, 2022 08:00 am ET
Eyenovia Announces Planned Chief Executive Officer Transition
Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™) therapeutics, today announced that Dr. Sean Ianchulev, co-founder, chief medical officer and chief...
May 12, 2022 04:05 pm ET
Eyenovia Reports First Quarter 2022 Financial Results
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced its financial and operating results for the...
May 05, 2022 08:00 am ET
Eyenovia to Report First Quarter 2022 Results on Thursday, May 12
Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, announced that the Company will release financial results for the first quarter ended March 31, 2022...
Apr 20, 2022 08:00 am ET
Eyenovia CEO, CMO and Chairman Dr. Sean Ianchulev to Present at Eyecelerator @ American Society of Cataract and Refractive Surgery (ASCRS) 2022
Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) investigational products, today announced that Dr. Sean Ianchulev, Chairman, Chief Executive Officer and Chief...
Apr 19, 2022 08:00 am ET
Eyenovia Announces Poster Presentation at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting
Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the Company will present an ePoster at the American Society of Cataract and...
Mar 28, 2022 04:05 pm ET
Eyenovia Reports Fourth Quarter and Full Year 2021 Financial Results
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced its financial results for the fourth...
Mar 21, 2022 08:00 am ET
Eyenovia to Report Fourth Quarter and Full Year 2021 Results on Monday, March 28
Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, announced that the Company will release financial results for the fourth quarter and full year ended...
Mar 15, 2022 08:00 am ET
Eyenovia Announces Positive Study Results Demonstrating that its Optejet® Delivery Technology Reduces Conjunctival Cell Toxicity from Preserved Ophthalmic Solutions to a Level Comparable with Non-Pres
Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, today announced positive results from a research study conducted in collaboration with Dr. Pedram...
Mar 04, 2022 07:00 am ET
Eyenovia Strengthens Balance Sheet with a $15 Million Institutional Capital Investment from Armistice Capital Master Fund Ltd.
Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the company has entered into a Securities Purchase Agreement with Armistice...
Feb 08, 2022 08:00 am ET
Eyenovia Concludes Type A Meeting with FDA Related to MydCombi™ NDA Resubmission
Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the company successfully completed a Type A meeting with the U.S. Food and Drug...
Feb 07, 2022 08:30 am ET
Eyenovia Announces Changes to Board of Directors
Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, today announced changes to its Board of Directors. Dr. Sean Ianchulev, Director, Chief Executive...
Nov 10, 2021 04:05 pm ET
Eyenovia Reports Third Quarter 2021 Financial Results
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced its financial results for the third...
Nov 08, 2021 08:00 am ET
Eyenovia to Participate in Myopia Panel Discussion at the Eyecelerator@AAO 2021 Meeting
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced that Dr. Sean Ianchulev, Chief Executive...
Nov 05, 2021 03:25 pm ET
CORRECTING AND REPLACING: Eyenovia to Report Third Quarter 2021 Results on Wednesday, November 10
Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, announced that the Company will release financial results for the third quarter ended September 30,...
Nov 04, 2021 04:05 pm ET
Eyenovia to Report Third Quarter 2021 Results on Thursday, November 11
Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, announced that the Company will release financial results for the third quarter ended September 30,...
Nov 04, 2021 08:00 am ET
Eyenovia Announces First Patient Enrolled in Phase 3 VISION-2 Trial of MicroLine for Presbyopia
Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the first patient has been enrolled in the Company’s second Phase 3 clinical...
Nov 04, 2021 03:14 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Eyenovia, Inc. - EYEN
NEW YORK, Nov. 4, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Eyenovia, Inc. ("Eyenovia" or the "Company") (NASDAQ: EYEN).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Nov 01, 2021 03:23 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Eyenovia, Inc. - EYEN
Pomerantz LLP is investigating claims on behalf of investors of Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Oct 25, 2021 08:00 am ET
Eyenovia Announces Reclassification of MydCombi(tm) as Drug-Device Combination Product by FDA
Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that MydCombi, the company’s proprietary, first-in-class combination microdose...
Aug 11, 2021 04:05 pm ET
Eyenovia Reports Second Quarter 2021 Financial Results
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced its financial and operating results for...
Aug 04, 2021 08:00 am ET
Eyenovia to Report Second Quarter 2021 Results on Wednesday, August 11
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, announced that the Company will release financial results...
Jul 19, 2021 07:00 am ET
Eyenovia to Participate in a Presbyopia Panel Discussion at Eyecelerator 2021
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that Eyenovia will be featured at the Company Showcase on July 22 at the Eyecelerator@ASCRS and will participate in a panel discussion, entitled, “Presbyopia: Everybody gets it... but ca
Jul 07, 2021 04:01 pm ET
Eyenovia to Participate in Two Upcoming Investor Conferences
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced that management will present a corporate...
Jun 15, 2021 08:00 am ET
Eyenovia highlights Recent Progress in Three Phase 3 Programs, NDA Review Progress and Licensing Agreements Totaling up to $100 Million in Potential Pre-Commercial Revenue
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today provided a corporate update on its pipeline with recent and upcoming milestones....
May 25, 2021 09:03 am ET
Eyenovia Announces Positive Topline Results from VISION-1 Phase 3 Clinical Study of MicroLine for the Treatment of Presbyopia
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of MAP™ therapeutics, today announced that its VISION-1 study evaluating the company’s proprietary pilocarpine formulation, MicroLine, for...
May 12, 2021 04:05 pm ET
Eyenovia Reports First Quarter 2021 Financial Results
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced its financial results for the first quarter...
May 10, 2021 08:30 am ET
Eyenovia Announces New $25 Million Credit Facility with Silicon Valley Bank
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the company has entered into a new $25 million credit financing facility...
May 05, 2021 08:00 am ET
Eyenovia to Report First Quarter 2021 Results on Wednesday, May 12
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced that the Company will release financial...
Apr 01, 2021 07:30 am ET
Eyenovia Announces Appointment of Renowned Ophthalmologist and Scientific Leader Dr. Julia Haller to its Board of Directors
“We are delighted to welcome Dr. Haller to our Board of Directors at such an exciting time for Eyenovia,” commented Dr. Sean Ianchulev, Chief Executive Officer and Chief Medical Officer of Eyenovia. “We believe that Dr. Haller’s decades of experience as an esteemed ophthalmic surgeon, scientist, professor, and business leader will be invaluable to the Eyenovia team as we strive to advance our late-stage ophthalmic pipeline and work towards our near-term clinical and regulatory milestones.”
Mar 25, 2021 04:05 pm ET
Eyenovia Reports Fourth Quarter and Full Year 2020 Financial Results
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced its financial results for the fourth...
Mar 23, 2021 07:30 am ET
Eyenovia and EVERSANA Announce Partnership to Support the Potential Launch and Commercialization of MydCombi™ for Mydriasis
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary Microdose Array Print (MAP™) platform technology, and
Mar 18, 2021 08:00 am ET
Eyenovia to Report Fourth Quarter and Full Year 2020 Results on Thursday, March 25
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced that the Company will release financial...
Mar 17, 2021 08:00 am ET
Eyenovia Announces Publication of MIST Pivotal Studies Demonstrating the Efficacy and Safety of its MAP™ Fixed-Combination Tropicamide-Phenylephrine Product for Mydriasis
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced the publication of “
Mar 10, 2021 08:00 am ET
Eyenovia to Participate in the 33rd Annual Roth Conference
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced that management will...
Mar 02, 2021 07:30 am ET
Eyenovia Announces FDA Acceptance of the MydCombi NDA
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for MydCombi™, a unique fixed combination mydriatic (pupil dilation) agent for pote
Feb 16, 2021 08:00 am ET
Eyenovia to Host Key Opinion Leader Webinar on Presbyopia
Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that it will host a Key Opinion Leader (KOL) webinar, entitled: “Presbyopia in...
Jan 26, 2021 07:30 am ET
Eyenovia to Present at the Ophthalmology Innovation Summit (OIS) Presbyopia Innovation Showcase
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that Dr. David Wirta will speak at the Ophthalmology Innovation Summit Presbyopia Innovation Showcase on January 28th.
Jan 06, 2021 08:00 am ET
Eyenovia to Participate in Presbyopia Panel Discussion at the LifeSci Partners 10th Annual Corporate Access Event
Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that Dr. Sean Ianchulev, Chief Executive Officer and Chief Medical Officer,...
Dec 29, 2020 07:00 am ET
Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis with MydCombi Targeting 80 Million Patient Encounters in the U.S. Annually
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company with Phase 3 programs in presbyopia, myopia and mydriasis, today announced that it has submitted a New Drug Application (NDA) to the U. S. Food and Drug Administration (FDA) for MydCombi™, a unique fixed combination mydriatic (pupil dilation) agent. If approved, MydComb
Dec 16, 2020 07:00 am ET
Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopia
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the first set of patients has been enrolled in the Company’s
Dec 03, 2020 07:00 am ET
Eyenovia Announces FDA Acceptance of IND for MicroLine for Presbyopia, Clearing Path to Initiate Phase 3 VISION Trial by Year End
Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the U. S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for MicroLine, a proprietary pilocarpine formulation for the improvement in
Nov 10, 2020 04:06 pm ET
Eyenovia Reports Third Quarter 2020 Financial Results
Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today reported its financial results for the third quarter ended September 30, 2020. “During...
Nov 05, 2020 08:00 am ET
Eyenovia to Report Third Quarter 2020 Results on Tuesday, November 10
Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the Company will release financial results for the third quarter...
Oct 13, 2020 07:00 am ET
Eyenovia to Host Investor Call to Discuss Recent Licensing Agreements Resulting in Total Potential License Payments and Development Cost Reimbursement and Savings of Approximately $100 Million
Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that management will host an investor conference call to discuss the company’s...
Oct 12, 2020 07:00 am ET
Bausch Health Licenses Eyenovia's Investigational Treatment For The Reduction Of Pediatric Myopia Progression In Children Ages 3-12
LAVAL, QC and NEW YORK, Oct. 12, 2020 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), Bausch + Lomb, its leading global eye health business, and Eyenovia, Inc., (NASDAQ: EYEN) ("Eyenovia"), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that an affiliate of Bausch Health has acquired an exclusive license in the United States and Canada for the development and commercialization of an investigational microdose formulation of atropine ophthalmic solution, which is being investigat
Oct 05, 2020 07:00 am ET
Eyenovia to Present Clinical Study Updates at the American Academy of Optometry Annual Meeting
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that Drs. Siddarth Rathi and April Jasper will present the latest analyses and updates from the company’s clinical studies at the
Sep 09, 2020 08:30 am ET
Eyenovia to Present at the 22nd Annual H.C. Wainwright Global Investment Conference
Eyenovia, Inc. (NASDAQ: EYEN) a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that Dr. Sean Ianchulev, Eyenovia’s Chief Executive Officer and Chief Medical...
Aug 24, 2020 08:30 am ET
Eyenovia, Inc. Announces Underwriters’ Full Exercise of Over-Allotment Option in Public Offering
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the underwriters of its previously announced public offering of common...
Aug 21, 2020 04:05 pm ET
Eyenovia, Inc. Announces Closing of Offering of Common Stock
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced the closing of its previously announced underwritten public offering of...
Aug 19, 2020 09:10 am ET
Eyenovia, Inc. Prices Public Offering of Common Stock
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced the pricing of an underwritten public offering of 3,333,334 shares of its...
Aug 18, 2020 04:03 pm ET
Eyenovia, Inc. Announces Proposed Public Offering of Common Stock
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that it intends to offer and sell shares of its common stock in an underwritten...
Aug 12, 2020 04:05 pm ET
Eyenovia Reports Second Quarter 2020 Financial Results
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today reported its financial results for the second quarter ended June 30, 2020. Second...
Aug 11, 2020 08:00 am ET
Eyenovia and Arctic Vision Announce Exclusive Collaboration and License Agreement to Develop and Commercialize MicroPine and MicroLine in Greater China and South Korea
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics and Arctic Vision, a clinical stage biotech company focused on developing and commercializing...
Jul 29, 2020 08:30 am ET
Eyenovia Announces Conference Call and Webcast for Second Quarter 2020 Financial Results
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the Company will release financial results for the second quarter ended...
Jun 30, 2020 04:05 pm ET
Eyenovia Resumes Recruitment of Phase III CHAPERONE Study for Progressive Myopia
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the Company has resumed patient enrollment for its Phase III CHAPERONE...
Jun 11, 2020 04:10 pm ET
Eyenovia, Inc. Announces Adjournment of 2020 Annual Meeting of Stockholders to June 30, 2020  and Change to a Virtual Meeting Format
Eyenovia, Inc. (NASDAQ: EYEN) a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that it adjourned its 2020 Annual Meeting of...
Jun 05, 2020 04:10 pm ET
Eyenovia Announces Intention to Adjourn 2020 Annual Meeting of Stockholders to June 30, 2020 and Change to a Virtual Meeting Format
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that it intends to convene and immediately...
May 13, 2020 04:05 pm ET
Eyenovia Reports First Quarter 2020 Financial Results
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced its financial results for the first quarter...
May 06, 2020 08:30 am ET
Eyenovia Announces Conference Call and Webcast for First Quarter 2020 Financial Results
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that the Company will release financial...
Mar 25, 2020 04:05 pm ET
Eyenovia Reports Fourth Quarter and Full Year 2019 Financial Results
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced its financial results for the fourth...
Mar 24, 2020 05:10 pm ET
Eyenovia, Inc. Announces Closing of Approximately $6.0 Million Private Placement
Eyenovia, Inc. (NASDAQ:EYEN) a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print technology, announced that today it closed its previously announced private...
Mar 23, 2020 06:35 pm ET
Eyenovia, Inc. Announces Approximately $6.0 Million Private Placement
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print technology, today announced that it has received subscriptions for a private...
Mar 11, 2020 08:30 am ET
Eyenovia Announces Conference Call and Webcast for Fourth Quarter and Full-Year 2019 Financial Results
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that the Company will release financial...
Mar 04, 2020 08:30 am ET
Eyenovia to Participate in Two Upcoming Investor Conferences
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced  that members of management will be...
Dec 19, 2019 08:30 am ET
Eyenovia Expands Scientific Advisory Board with Two Experts in Optometry
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that Professor Mark Bullimore, PhD and...
Nov 13, 2019 04:05 pm ET
Eyenovia Reports Third Quarter 2019 Financial Results
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced its financial results for the third quarter...
Oct 31, 2019 08:30 am ET
Eyenovia Announces Conference Call and Webcast for Third Quarter 2019 Financial Results
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that the Company will release financial...
Oct 29, 2019 04:05 pm ET
Eyenovia Advances MicroLine for the Treatment of Presbyopia Towards Phase III Development and Reprioritizes Late-Stage Ophthalmology Pipeline
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that the Company is advancing the...
Oct 02, 2019 08:30 am ET
Eyenovia to Participate in Multiple Upcoming Medical Meetings
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that it will be presenting at multiple...
Sep 03, 2019 08:30 am ET
Eyenovia to Present at Two Upcoming Investor Conferences
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that Dr. Sean Ianchulev, Eyenovia’s Chief...
Aug 12, 2019 04:05 pm ET
Eyenovia Reports Second Quarter 2019 Financial Results
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced its financial results for the second...
Aug 06, 2019 08:30 am ET
Eyenovia Announces Conference Call and Webcast for Second Quarter 2019 Financial Results
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that the Company will release financial...
Jul 16, 2019 04:05 pm ET
Eyenovia, Inc. Announces Underwriters’ Full Exercise of Over-Allotment Option in Public Offering
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print technology, today announced that the underwriters of its previously announced...
Jul 15, 2019 04:30 pm ET
Eyenovia, Inc. Announces Closing of Public Offering
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print technology, today announced the closing of its previously announced underwritten...
Jul 11, 2019 09:00 am ET
Eyenovia, Inc. Prices Public Offering of Common Stock
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print technology, today announced the pricing of an underwritten public offering of...
Jul 10, 2019 04:07 pm ET
Eyenovia, Inc. Announces Proposed Public Offering of Common Stock
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print technology, today announced that it intends to offer and sell shares of its...
Jun 04, 2019 08:30 am ET
Eyenovia Enrolls First Patient in Phase III CHAPERONE Study for Progressive Myopia
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that it has initiated its MicroPine Phase...
May 14, 2019 06:30 am ET
Eyenovia Reports First Quarter 2019 Financial Results
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced its financial results for the first quarter...
May 06, 2019 08:30 am ET
Eyenovia Announces Presentation of Successful Phase 3 Studies at the ASCRS-ASOA Annual Meeting
Eyenovia, Inc. (NASDAQ: EYEN) a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced the safety and efficacy results from the...
May 01, 2019 08:30 am ET
Eyenovia Announces Conference Call and Webcast for First Quarter 2019 Financial Results
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that the Company will release financial...
Apr 18, 2019 08:30 am ET
Consolidated Research: 2019 Summary Expectations for Stepan, Helius Medical Technologies, ReWalk Robotics, Funko, Alimera Sciences, and Eyenovia — Fundamental Analysis, Key Performance Indications
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Stepan Company (NYSE:SCL), Helius Medical Technologies, Inc. (NASDAQ:HSDT),...
Mar 27, 2019 06:30 am ET
Eyenovia Reports Fourth Quarter and Full Year 2018 Financial Results
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced its financial results for the fourth...
Mar 13, 2019 08:30 am ET
Eyenovia Announces Conference Call and Webcast for Fourth Quarter and Full-Year 2018 Financial Results
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that the Company will release financial...
Mar 04, 2019 08:30 am ET
Eyenovia to Participate in Two Upcoming Investor Conferences
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that members of management will be...
Feb 25, 2019 08:30 am ET
Eyenovia Announces Confirmatory Results from Second MicroStat Phase III Registration Study for Mydriasis
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced positive results from its second MicroStat...
Feb 20, 2019 08:31 am ET
Thinking about buying stock in Advanced Micro Devices, Art S Way MFG Co., Eyenovia Inc., NVIDIA, or Tesla Inc.?
NEW YORK, Feb. 20, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMD, ARTW, EYEN, NVDA, and TSLA.
Feb 13, 2019 08:30 am ET
Eyenovia confirms expanded MicroProst Phase III indication to enroll broad patient population for IOP lowering
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today confirmed a broad patient population for its Phase...
Feb 06, 2019 08:30 am ET
Eyenovia Announces FDA Acceptance of IND Application for MicroPine to Reduce the Progression of Myopia
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that the U.S. Food and Drug Administration...
Jan 30, 2019 07:00 am ET
Eyenovia Announces Positive Results in the MicroStat MIST-1 Phase III Registration Study for Mydriasis
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced positive results from the MicroStat Phase 3...
Dec 19, 2018 09:05 am ET
Eyenovia Prices Public Offering of Common Stock
Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print technology, has priced its underwritten public...
Dec 03, 2018 09:00 am ET
Eyenovia Completes Patient Enrollment in MicroStat MIST-1 Study and Enrolls First Patient in MIST-2 Study
Eyenovia, Inc. (NASDAQ: EYEN) today announced that it has completed patient enrollment in its Phase III MIST-1 study and enrolled the first patient in its second Phase III study, the MIST-2 trial, for the Company’s Phase III MicroStat program for...
Nov 28, 2018 04:05 pm ET
Eyenovia Announces Publication of its PG21 Phase II Trial Results Demonstrating Robust IOP Lowering Effect and Patient Usability
Eyenovia, Inc. (NASDAQ: EYEN) today announced that the full results of its Phase II PG21 study have been published in the article “Latanoprost with high precision, piezo-print microdose delivery for IOP lowering: clinical results of the PG21 study...
Nov 26, 2018 04:26 pm ET
Eyenovia Initiates Phase III MicroStat Program for Pharmacologic Mydriasis: Enrolls First Patient in MIST-1 Study
NEW YORK, Nov. 26, 2018 /PRNewswire/ -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print technology, today announced that it has enrolled the first patient in the first of two Phase III trials (MIST-1 and MIST-2) of the Company's MicroStat program for pharmacologic mydriasis, or dilation of the pupil for an eye exam. The studies will investigate the safety and efficacy of the Company's first-in-class fixed-combination phenylephrine 2.5% - tropicamide 1% ophthalmic solution,
Nov 26, 2018 09:00 am ET
Eyenovia Initiates Phase III MicroStat Program for Pharmacologic Mydriasis: Enrolls First Patient in MIST-1 Study
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print technology, today announced that it has enrolled the first patient in the first...
Nov 21, 2018 08:50 am ET
Market Trends Toward New Normal in Wilhelmina International, Eyenovia, aTyr Pharma, Avinger, Viacom, and Axsome Therapeutics — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Wilhelmina International, Inc. (NASDAQ:WHLM), Eyenovia, Inc....
Nov 13, 2018 07:30 am ET
Eyenovia Announces FDA Acceptance of MicroStat IND Application for Mydriasis
Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-dosed medications topically to the eye, today announced that the U.S. Food and...
Nov 13, 2018 06:30 am ET
Eyenovia Reports Third Quarter 2018 Financial Results
Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver microdosed medications topically to the eye, today announced financial results for...
Nov 01, 2018 08:30 am ET
Eyenovia Announces Conference Call and Webcast for Third Quarter 2018 Financial Results
Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver microdosed medications topically to the eye, today announced that the Company will...
Oct 23, 2018 09:00 am ET
Eyenovia to Present at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology 2018
Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver microdosed medications topically to the eye, today announced that Dr. Sean...
Oct 05, 2018 08:01 pm ET
Johnson Fistel Announces Investigations of PPDAI Group Inc., Menlo Therapeutics Inc., Eyenovia, Inc. and Dragon Victory International Limited; Investors with Losses Encouraged to Contact Firm
SAN DIEGO, Oct. 5, 2018 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against:
Sep 24, 2018 07:22 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors that it is Investigating Possible Securities Fraud Violations by Certain Officers and Directors of Menlo Therapeutics, Hill International, and Eyenovia on
Bragar Eagel Squire, P.C. reminds investors that it is investigating potential claims on behalf of stockholders of Menlo Therapeutics Inc., Hill International, Inc., and Eyenovia, Inc.  Additional information about each potential action can be...
Sep 19, 2018 08:30 am ET
Eyenovia to Participate in Panel Presentation at OSN New York 2018
Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver microdosed medications topically to the eye, today announced that Dr. Sean...
Sep 18, 2018 07:30 am ET
Eyenovia to Present at the Ladenburg Thalmann 2018 Healthcare Conference
Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver microdosed medications topically to the eye, today announced that Dr. Sean...
Aug 21, 2018 07:30 am ET
Eyenovia to Present at the 20th Annual H.C. Wainwright Global Investment Conference
Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver microdosed medications topically to the eye, today announced that Dr. Sean...
Aug 17, 2018 03:39 pm ET
Bragar Eagel & Squire, P.C. is Investigating Eyenovia, Inc. (EYEN) on Behalf of Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel Squire, P.C. is investigating potential claims against Eyenovia, Inc. (NASDAQ: EYEN).  Our investigation concerns whether Eyenovia has violated the federal securities laws and/or engaged in other unlawful business practices. The...
Aug 16, 2018 02:07 pm ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Eyenovia, Inc. (EYEN)
NEW YORK, Aug. 16, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Eyenovia, Inc. ("Eyenovia" or the "Company") (NASDAQ: EYEN). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/eyen.
Aug 16, 2018 01:43 pm ET
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Eyenovia, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Eyenovia, Inc. (“Eyenovia” or “the Company”) (NASDAQ:
Aug 15, 2018 06:56 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Eyenovia, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Eyenovia, Inc. (“Eyenovia” or “the Company”) (NASDAQ:
Aug 15, 2018 04:30 pm ET
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Eyenovia, Inc. – EYEN
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Eyenovia, Inc. (NASDAQ: EYEN) resulting from allegations that Eyenovia may have issued materially misleading business information to the investing public.
Aug 14, 2018 06:30 am ET
Eyenovia Reports Second Quarter 2018 Financial Results
Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver microdosed medications topically to the eye, today announced financial results for...
Aug 13, 2018 08:30 am ET
Eyenovia’s EYN PG21 Trial Evaluating High-Precision Microdose of Latanoprost Demonstrates Robust Intraocular Pressure Lowering and Patient Usability
Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver microdosed medications topically to the eye, today announced positive results of its...
Jul 31, 2018 08:30 am ET
Eyenovia Announces Conference Call and Webcast for Second Quarter 2018 Financial Results
Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced that the...
Jul 09, 2018 07:30 am ET
Eyenovia Appoints Michael Rowe as Vice President of Marketing Ahead of Initiation of Multiple Phase III Programs
Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced the...
Jun 11, 2018 07:30 am ET
Eyenovia to Present at the JMP Securities 2018 Life Sciences Conference
Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced that Dr. Sean...
Jun 05, 2018 09:13 pm ET
Glancy Prongay & Murray LLP Continues Investigation on Behalf of Eyenovia, Inc. Investors (EYEN)
Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of Eyenovia, Inc. (NASDAQ: EYEN) investors concerning the Company and its directors’ and officers’ possible violations of state laws.
Jun 05, 2018 07:30 am ET
Eyenovia Receives Notices of Allowance from USPTO on Two Additional Patent Applications for Ophthalmic Drug Delivery
Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced it has...
May 09, 2018 06:30 am ET
Eyenovia Reports First Quarter 2018 Financial Results and Completion of EYN PG21 Study
Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced financial...
Apr 19, 2018 08:30 am ET
Eyenovia Announces Conference Call and Webcast for First Quarter 2018 Financial Results
NEW YORK, April 19, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced that the...
Apr 03, 2018 08:31 pm ET
Glancy Prongay & Murray LLP Announces Investigation on Behalf of Eyenovia, Inc. Investors (EYEN)
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Eyenovia, Inc. (NASDAQ: EYEN) investors concerning the Company and its directors’ and officers’ possible violations of state laws.
Apr 02, 2018 06:30 am ET
Eyenovia Announces Fourth Quarter and Full Year 2017 Financial Results
Successfully Completed EYN PG21 Study Evaluating Usability and IOP Lowering with Micro-Therapeutic Latanoprost
Mar 26, 2018 04:05 pm ET
Eyenovia Appoints Three Industry Veterans to Board of Directors
NEW YORK, March 26, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced that it...
Mar 19, 2018 08:30 am ET
Eyenovia Announces Conference Call and Webcast for Fourth Quarter and Full Year 2017 Financial Results
NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- Eyenovia Inc. (“Eyenovia”) (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, announced today that...
Feb 27, 2018 08:30 am ET
Eyenovia to Present at the 30th Annual ROTH Conference
NEW YORK, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Eyenovia Inc. (“Eyenovia”) (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced that...
Feb 21, 2018 08:30 am ET
Eyenovia Advances MicroPine for Myopia into Phase III Clinical Development and Appoints Stanford Professor Dr. Douglas Fredrick to its Scientific Advisory Board and Myopia Program Steering Committee
NEW YORK, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Eyenovia Inc. (“Eyenovia”), (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye,  today announced that...
Jan 29, 2018 04:05 pm ET
Eyenovia Announces Closing of $27.3 Million Initial Public Offering
NEW YORK, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Eyenovia Inc. (“Eyenovia”), (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced the...
Jan 25, 2018 06:30 am ET
Eyenovia Announces Pricing of Initial Public Offering
NEW YORK, Jan. 25, 2018 (GLOBE NEWSWIRE) -- Eyenovia Inc. (“Eyenovia”), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced the pricing...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.